November 18, 2025 — Leads & Copy — Vyome Holdings, Inc. (NASDAQ: HIND) has reported its financial results and corporate and clinical milestones following its Nasdaq listing.
The announcement marks Vyome’s first full reporting period as a publicly traded company. Vyome is an AI-focused clinical-stage company aiming to speed up drug development for immuno-inflammatory and potential orphan indications.
Krishna Gupta, Chairman of Vyome, stated that the company is building its business with a focus on shareholder value by addressing inflammation-related medical and mental problems. He cited their expertise and access to the U.S.-India innovation corridor as a unique strength. He also mentioned the interim results for their drug targeting malignant fungating wound (MFW).
Vyome CEO Venkat Nelabhotla noted the company’s efficient transition to the public markets. He added that the Phase 2 results for VT-1953 validate the potential of their immuno-inflammation platform.
The lead program, VT-1953, a topical agent for symptoms of malodor and pain in malignant fungating wounds, demonstrated clinical momentum.
Interim Phase 2 study data showed statistically significant reductions in malodor (P<0.001), the primary endpoint, as well as reductions in pain and improvements in quality of life. VT-1953 has shown an excellent safety profile.
FDA discussions on the pivotal study design and Orphan drug designation are planned for the first half of 2026.
MFW, affecting 5–14% of advanced cancer patients, leads to emotional and social burden due to malodor. The market opportunity for MFW is estimated at $1 billion in the U.S., and VT-1953 could be the only FDA-approved solution.
Full data of Phase 2 readouts for VT-1953 are expected in the first week of December 2025.
Strong preclinical efficacy was reported for VT-1908 eye drops in uveitis models in the third quarter, reinforcing its promise as a steroid-sparing candidate. FDA interactions for VT-1908 are scheduled for the first half of 2026.
Key financial highlights for the third quarter of 2025 include:
- Total cash, cash equivalents, and short-term investments of $5.7 million, providing an expected runway through the end of 2026.
- Net loss primarily due to one-time merger and financing-related expenses.
- Clean capital structure with 5,556,295 shares outstanding and no preferred stock.
Vyome Holdings, Inc. will host a conference call and webcast on Thursday, November 20, at 10:00 a.m. ET to discuss the results. To access the webcast, please use the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=PzMQuQGB or dial in at 877-407-5795 (U.S. toll-free) / +1 201-689-8722 (international).
Vyome Holdings, Inc. aims to develop a platform across the US-India innovation corridor, focusing on clinical-stage assets to help patients with immuno-inflammatory conditions. The company seeks to deliver value to shareholders cost-efficiently while maintaining quality and safety standards.
Source: Vyome Holdings, Inc.
